KLRS Reports $104.9M Cash Balance, $7.6M R&D Expenses, $10.9M Net Loss, Advances Phase 1b/2 Trial
Kalaris Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $4.90
+6.9% in 7d after detection
Post-detection moves
1h
—
1d
+0.8%
3d
+2.3%
7d
+6.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS